title: Update on New and Emerging Therapies in the Management of Psoriasis.
abstract: Tumor necrosis factor inhibitors are a mainstay of treatment for patients with psoriasis who require systemic therapy. Since the approval of several of these agents, other biologic agents and small molecules have been developed; some of these have been approved recently by the US Food and Drug Administration, and others have shown great promise in clinical trials. The currently available and emerging treatments for psoriasis offer clinicians and patients an expanded list of options for individualizing treatment, potentially resulting in higher levels of improvement in both the disease process and quality of life. Semin Cutan Med Surg 34(supp2):S34-S36 © 2015 published by Frontline Medical Communications.
authors.affiliation: Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Gordon
keywords: Apremilast; Janus kinase inhibitors; brodalumab; guselkumab; interleukin-12/23 inhibitors; interleukin-17 inhibitors; interleukin-23 inhibitors; ixekizumab; phosphodiesterase-4
  inhibitors; psoriasis; secukinumab; tildrakizumab; tofacitinib; tumor necrosis factor inhibitors; ustekinumab